Russia Proposes Using Tobacco License Fees to Fund COPD Treatment

May.19
Russia Proposes Using Tobacco License Fees to Fund COPD Treatment
Russia’s Democratic Forces have proposed using revenue from retail licenses for nicotine-containing products to fund treatment for chronic obstructive pulmonary disease (COPD).

Key Points:

 

1.The licensing program is expected to bring in an additional 6 billion rubles to the budget annually.

 

2.Of the total, 3 billion rubles will be specifically allocated for the treatment of COPD patients.

 

3.Chronic Obstructive Pulmonary Disease (COPD) has become the second leading cause of death among individuals aged 35-45.

 


 

According to the Russian media outlet Tehnowar, the Russian Democratic Forces have proposed using funds obtained from the introduction of retail licenses for nicotine products to support the fight against Chronic Obstructive Pulmonary Disease (COPD).

 

The assistant vice president of the association made the above remarks at the "Shemashko Russian Medical Forum."

 

This concept involves using funds from the introduction of retail licenses for nicotine products to support the fight against chronic obstructive pulmonary disease.

 

According to the organization's initial estimates, the implementation of a licensing system is expected to generate over 60 billion rubles ($7.4 billion) in revenue annually. Of this amount, 30 billion rubles ($3.7 billion) would be sufficient to provide treatment for all COPD patients in Russia. At least 7% of the Russian population is affected by this disease. Additionally, there is a growing trend of lung cancer among younger individuals, with lung cancer ranking second as the leading cause of respiratory disease-related deaths in patients aged 35-45.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

B.C. Plans World’s First E-Cigarette Public Health Accountability Law Aimed at “Deceptive Marketing”
B.C. Plans World’s First E-Cigarette Public Health Accountability Law Aimed at “Deceptive Marketing”
British Columbia, Canada is advancing what it calls the world’s first e-cigarette Public Health Accountability law, granting the government authority to sue companies for “deceptive marketing.” The move puts public-health risks at the center of vaping industry compliance.
Oct.10 by 2FIRSTS.ai
Zyn Retailers to Pay $3M Settlement for Violating San Francisco’s Flavored Nicotine Ban
Zyn Retailers to Pay $3M Settlement for Violating San Francisco’s Flavored Nicotine Ban
San Francisco’s City Attorney’s Office has reached a $3 million settlement with three online tobacco retailers accused of illegally selling flavored Zyn nicotine pouches, violating the city’s 2017 ban on flavored tobacco products.
Oct.29
Lao Shuts Down Nearly 300 Online Vape Stores in Joint Crackdown with WHO and Meta
Lao Shuts Down Nearly 300 Online Vape Stores in Joint Crackdown with WHO and Meta
In a coordinated effort with the World Health Organization (WHO) and Meta, the Lao Ministry of Health has taken 288 online e-cigarette stores with more than 759,599 members offline, reinforcing the country’s total ban on e-cigarettes under the National Tobacco Control Law.
Nov.20 by 2FIRSTS.ai
Dagestan Proposes Pilot Ban on E-Cigarette Sales, Submits Request to State Duma
Dagestan Proposes Pilot Ban on E-Cigarette Sales, Submits Request to State Duma
The head of Russia’s Republic of Dagestan has proposed a region-wide ban on the retail sale of e-cigarettes and has written to the State Duma seeking to designate Dagestan as a pilot region for a comprehensive e-cigarette sales ban.
Oct.21 by 2FIRSTS.ai
Scandinavian Tobacco Group Reports Q3 2025 Results and Narrows Full-Year Guidance
Scandinavian Tobacco Group Reports Q3 2025 Results and Narrows Full-Year Guidance
Scandinavian Tobacco Group (STG) reported net sales of DKK 2.4 billion for Q3 2025, in line with last year. EBITDA before special items reached DKK 519 million with a 22.0% margin. Handmade Cigars and Next Generation Products saw organic growth, while Machine-Rolled Cigars and Smoking Tobacco declined. The company narrowed its full-year guidance.
Nov.12 by 2FIRSTS.ai
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.
Nov.26